Status
Conditions
Treatments
About
When patients progress to the final stage of chronic kidney disease (CKD) and require hemodialysis treatment, they typically have lost so much muscle function that they are no longer physically independent. However, due to disease- and hemodialysis-related muscle catabolism, dietary protein and exercise interventions are only capable to attenuate the decline in physical function of patients on hemodialysis treatment. Therefore, lifestyle interventions to increase muscle function should be implemented before hemodialysis is required. However, it is still a matter of debate whether muscle protein synthesis rates of patients with advanced CKD can be increased with a patient-tailored dietary protein and exercise intervention.Therefore, the current study will assess MPS rates during habitual lifestyle and during an interventional program including dietary protein and exercise in patients with advanced CKD. In addition, we will compare MPS rates during free-living conditions between patients with advanced CKD and healthy controls.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
In order to be eligible to participate in this study, a patient with CKD must meet all of the following criteria:
In order to be eligible to participate in this study, a healthy subject must meet all of the following criteria:
A potential subject with CKD who meets any of the following criteria will be excluded from participation in this study:
Insulin-dependent diabetes mellitus or two or more oral glucose lowering medications
Active inflammatory disease / malignancies
Uncontrolled hypertension (>160/100mm Hg), unstable angina pectoris, or arrhythmia
Pulmonary disease restricting exercise performance (e.g. COPD)
A history of neuromuscular problems
Cognitive Impairment
Diagnosed GI tract diseases / dysphagia
Allergies to milk proteins / Lactose intolerance
Pregnancy
Hospitalization <1 months prior to study period
Participation in any structured exercise program
Any medications known to affect protein metabolism (i.e. corticosteroids or prescription strength acne medications).
Use of DOAC, vitamin-K-antagonist, or multiple anticoagulants.
Dialysis treatment or previous kidney transplantation
Insulin-dependent diabetes mellitus or two or more oral glucose lowering medications
Active inflammatory disease / malignancies
Uncontrolled hypertension (>160/100mm Hg), unstable angina pectoris, or arrhythmia
Pulmonary disease restricting exercise performance (e.g. COPD)
A history of neuromuscular problems
Cognitive Impairment
Diagnosed GI tract diseases / dysphagia
Allergies to milk proteins / Lactose intolerance
Pregnancy
Hospitalization <1 months prior to study period
Participation in any structured exercise program
Any medications known to affect protein metabolism (i.e. corticosteroids or prescription strength acne medications).
Use of DOAC, vitamin-K-antagonist, or multiple anticoagulants.
Primary purpose
Allocation
Interventional model
Masking
40 participants in 2 patient groups
Loading...
Central trial contact
Floris K Hendriks, M.D.; Luc JC van Loon, Prof. Dr.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal